Paragon 28's stock has seen a significant recovery from its low point of $4.89 in the third quarter of 2024, with InvestingPro data showing an impressive six-month return of 38.4%.

M VM Partners, LLC, a significant stakeholder in Paragon 28, Inc. (NASDAQ:FNA), disclosed the sale of 111,465 shares of common stock, valued at approximately $1.32 million. The transactions ...

Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the expiration of ...

Paragon 28 (NYSE:FNA – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($ ...

ENGLEWOOD, Colo., March 07, 2025--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to ...

Paragon 28 shares rose 8.4% after Zimmer Biomet Holdings agreed to acquire the company. Shares were trading around $13.02. The stock is up about 2.6% over the last year. Zimmer, a medical ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Paragon 28, Inc. (NYSE: FNA) to Zimmer Biomet Holdings, Inc. for $13.00 per share in ...

Paragon 28 stock opened at $13.03 on Monday. The company has a debt-to-equity ratio of 0.79, a current ratio of 3.50 and a quick ratio of 1.60. Paragon 28, Inc. has a 12 month low of $4.65 and a ...

Paragon 2 (FNA) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976in connection with the previously announced acquisition of Paragon 28 ...